BioCentury

8:00 AM GMT, Jan 7, 2008
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 1/4 cls
Amgen (NASDAQ:AMGN) Lazard Joel Sendek Upgrade Hold (from sell) -5% $44.80
Sendek sees the stock as fairly valued at $46, a five-year low. Still, he expects Amgen to report disappointing 4Q07 earnings and FDA's Oncologic Drugs Advisory Committee (ODAC) to place further restrictions on erythropoiesis-stimulating agents (ESAs) at its meeting in 1Q08, which could lead to more share price deterioration. Amgen markets two ESAs: Aranesp darbepoetin alfa for cancer and renal indications, and Epogen epoetin alfa for chronic renal failure.
CombinatoRx (NASDAQ:CRXX) Piper Jaffray Edward

Read the full 988 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.